Janux Therapeutics Inc (JANX) AI Stock Analysis

• Market Cap: $881.17M
• Dividend Yield: N/A
• Average Volume (3M): 2.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: -23.37%
• EPS Growth: -42.45%
• Country: US
• Employees: 91
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 60,147,808
• 10 Day Avg. Volume: 3,835,408
• 30 Day Avg. Volume: 2,045,240
• PEG Ratio: 13.76
• Price to Book (P/B): 2.81
• Price to Sales (P/S): 271.80
• P/FCF Ratio: -65.15
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 54.95
• Enterprise Value/Gross Profit: 57.85
• Enterprise Value/Ebitda: -4.19
• 1Y Price Target: $56.42
• Price Target Upside: 300.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): -1.95
• Revenue Forecast (FY): $10.06M

• Rating: 45 Neutral
• Price Target: $15.50 ▲(9.93% Upside)

Janux Therapeutics Inc's overall stock score is primarily influenced by its strong revenue growth and robust balance sheet, which are offset by ongoing profitability challenges and negative cash flows. The technical analysis suggests a bearish trend, though the oversold RSI indicates potential for a rebound. The valuation is unattractive due to negative earnings and lack of dividends.

Positive Factors

Strong Balance Sheet

A strong balance sheet with minimal debt provides financial stability and flexibility, enabling Janux Therapeutics to invest in R&D and withstand market fluctuations.

Innovative Product Pipeline

Positive clinical data for JANX007 highlights the potential of Janux's innovative pipeline, enhancing its competitive position in the immunotherapy market.

Revenue Growth

Consistent revenue growth indicates successful strategic partnerships and product development, supporting long-term financial health and market expansion.

Negative Factors

Profitability Challenges

Ongoing profitability challenges due to high operational costs and negative margins may hinder long-term financial sustainability and investment capacity.

Negative Cash Flow

Negative cash flow from operations indicates reliance on external financing, which could limit strategic flexibility and increase financial risk over time.

Heavy Reliance on Equity Financing

High reliance on equity financing may dilute existing shareholders and limit future capital-raising options, impacting long-term growth and shareholder value.

Janux Therapeutics Inc Business Overview & Revenue Model

Company Description

Janux Therapeutics Inc (JANX) is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company utilizes its proprietary platform technology to create a new class of therapeutics designed to selectively activate the immune system against tumors. Janux specializes in the development of its product candidates that aim to enhance the body's ability to fight cancer while minimizing adverse effects on healthy tissues. The company is advancing several candidates through preclinical and clinical stages, targeting various types of cancers.

How the Company Makes Money

Janux Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which often involve upfront payments, milestone payments, and royalties on future sales of products developed from their technologies. Additionally, the company may generate revenue through grants and funding from government entities or non-profit organizations dedicated to cancer research. As they advance their product candidates through clinical trials and towards commercialization, potential licensing agreements with other firms can also serve as a significant source of income.

Janux Therapeutics Inc Financial Statement Overview

Summary

Janux Therapeutics Inc demonstrates strong revenue growth and a robust balance sheet with minimal debt. Despite these strengths, the company is still facing challenges with profitability and cash generation from operations, as indicated by negative net income and operating cash flows. The company remains reliant on financing to support its cash needs.

Income Statement

Janux Therapeutics Inc has shown a significant increase in revenue from $8.08 million in 2023 to $10.59 million in 2024, representing a growth rate of approximately 30.4%. However, the company continues to operate at a net loss with a net profit margin of -651.6% for 2024. The gross profit margin remains high at 100%, but negative EBIT and EBITDA margins indicate operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The company maintains a strong equity base with a stockholders' equity of $1.02 billion, indicating solid foundational support. The debt-to-equity ratio is low at 0.02, suggesting minimal leverage which reduces financial risk. However, the equity ratio at 96.3% shows heavy reliance on equity financing. Return on equity is negative, reflecting ongoing losses.

Cash Flow

Operating cash flow is negative, showing the company is not generating cash from its core operations. Nevertheless, there was an improvement in free cash flow from -$52.43 million in 2023 to -$44.17 million in 2024, reflecting a positive growth rate in free cash flow. The financing cash flow remains strong due to significant cash inflows from financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.00M	10.59M	8.08M	8.61M	3.64M	0.00
Gross Profit	9.50M	8.53M	6.13M	7.77M	3.64M	-13.00K
EBITDA	-131.28M	-96.79M	-71.02M	-66.25M	-32.82M	-6.57M
Net Income	-101.89M	-68.99M	-58.29M	-63.06M	-32.67M	-6.78M
Balance Sheet
Total Assets	1.02B	1.06B	380.41M	364.01M	379.82M	16.22M
Cash, Cash Equivalents and Short-Term Investments	988.99M	1.03B	344.03M	327.02M	374.96M	7.81M
Total Debt	22.66M	23.02M	24.54M	25.30M	194.00K	0.00
Total Liabilities	48.21M	38.73M	36.06M	43.27M	13.50M	30.86M
Stockholders Equity	976.55M	1.02B	344.35M	320.74M	366.33M	-14.64M
Cash Flow
Free Cash Flow	-71.40M	-44.17M	-52.42M	-49.37M	-18.46M	-4.37M
Operating Cash Flow	-70.42M	-43.81M	-50.58M	-42.92M	-16.98M	-4.37M
Investing Cash Flow	-296.60M	-258.02M	-41.19M	58.27M	-340.96M	0.00
Financing Cash Flow	388.65M	713.24M	59.55M	500.00K	386.52M	11.52M

Janux Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Negative. The current price of 14.1 is below the 20-day moving average (MA) of 22.18, below the 50-day MA of 25.25, and below the 200-day MA of 25.75, indicating a bearish trend. The MACD of -3.66 indicates Positive momentum. The RSI at 26.62 is Positive, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JANX.

Janux Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRDN	60 Neutral	$3.14B	-9.09	-47.40%	―	23340.07%	18.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	45 Neutral	$881.17M	-8.42	-12.48%	―	-23.37%	-42.45%
PHVS	42 Neutral	$1.58B	―	-51.81%	―	―	-20.08%
EWTX	40 Underperform	$2.41B	-14.15	-30.02%	―	―	-5.73%
BHVN	40 Underperform	$1.42B	-1.43	-522.08%	―	―	18.76%
VERA	39 Underperform	$3.38B	-12.17	-73.25%	―	―	-53.44%

Janux Therapeutics Inc Corporate Events

Janux Therapeutics Announces Departure of Chief Strategy Officer

Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc., ceased to serve as Chief Strategy Officer and departed from the company effective September 18, 2025. His departure was classified as a termination without ‘Cause’ according to the company’s Change in Control and Severance Benefit Plan.